Boston Scientific (BSX) has wrapped up the sale of its neurovascular business to Stryker (SYK) for $1.5B, and says it's prepaying $600M in senior notes due in June. BSX takes a pretax charge of $15M in Q4 for accelerated interest; shares +0.8%.